Chronic pain: the burden of disease and treatment innovations
Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic impact. Effi cacy and tolerability problems are encountered with all therapeutic strat...
Main Authors: | S. Monti, R. Caporali |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2015-10-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/840 |
Similar Items
-
Tapentadol extended release for the management of chronic neck pain
by: Billeci D, et al.
Published: (2017-03-01) -
Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality
by: Renato Vellucci, et al.
Published: (2021-04-01) -
First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18
by: Finkel JC, et al.
Published: (2019-06-01) -
Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients
by: Muse D, et al.
Published: (2019-05-01) -
Tapentadol: an effective option for the treatment of back pain
by: Coluzzi F, et al.
Published: (2019-05-01)